{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:57:42Z","timestamp":1791313062844,"version":"4.3.1"},"reference-count":49,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,10,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immunomodulators are effective in controlling hematologic malignancy by initiating or reactivating host antitumor immunity to otherwise poorly immunogenic and immune suppressive cancers. We aimed to boost antitumor immunity in B-cell lymphoma by developing a tumor cell vaccine incorporating \u03b1-galactosylceramide (\u03b1-GalCer) that targets the immune adjuvant properties of NKT cells. In the E\u03bc-myc transgenic mouse model, single therapeutic vaccination of irradiated, \u03b1-GalCer\u2013loaded autologous tumor cells was sufficient to significantly inhibit growth of established tumors and prolong survival. Vaccine-induced antilymphoma immunity required NKT cells, NK cells, and CD8 T cells, and early IL-12\u2013dependent production of IFN-\u03b3. CD4 T cells, gamma\/delta T cells, and IL-18 were not critical. Vaccine treatment induced a large systemic spike of IFN-\u03b3 and transient peripheral expansion of both NKT cells and NK cells, the major sources of IFN-\u03b3. Furthermore, this vaccine approach was assessed in several other hematopoietic tumor models and was also therapeutically effective against AML-ETO9a acute myeloid leukemia. Replacing \u03b1-GalCer with \u03b2-mannosylceramide resulted in prolonged protection against E\u03bc-myc lymphoma. Overall, our results demonstrate a potent immune adjuvant effect of NKT cell ligands in therapeutic anticancer vaccination against oncogene-driven lymphomas, and this work supports clinical investigation of NKT cell\u2013based immunotherapy in patients with hematologic malignancies.<\/jats:p>","DOI":"10.1182\/blood-2012-04-426643","type":"journal-article","created":{"date-parts":[[2012,8,30]],"date-time":"2012-08-30T00:19:59Z","timestamp":1346285999000},"page":"3019-3029","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":63,"title":["NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma"],"prefix":"10.1182","volume":"120","author":[{"given":"Stephen R.","family":"Mattarollo","sequence":"first","affiliation":[{"name":"Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Australia;"},{"name":"University of Queensland Diamantina Institute, Princess Alexandra Hospital, Woolloongabba, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison C.","family":"West","sequence":"additional","affiliation":[{"name":"Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Australia;"},{"name":"Cancer Therapeutics Program, Peter MacCallum Cancer Centre, East Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Steegh","sequence":"additional","affiliation":[{"name":"Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Duret","sequence":"additional","affiliation":[{"name":"Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Paget","sequence":"additional","affiliation":[{"name":"Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Martin","sequence":"additional","affiliation":[{"name":"Cancer Therapeutics Program, Peter MacCallum Cancer Centre, East Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey M.","family":"Matthews","sequence":"additional","affiliation":[{"name":"Cancer Therapeutics Program, Peter MacCallum Cancer Centre, East Melbourne, Australia;"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"Shortt","sequence":"additional","affiliation":[{"name":"Cancer Therapeutics Program, Peter MacCallum Cancer Centre, East Melbourne, Australia;"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Chesi","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, Mayo Clinic, Scottsdale, AZ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, Mayo Clinic, Scottsdale, AZ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bots","sequence":"additional","affiliation":[{"name":"LEXOR, Academic Medical Center, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Zuber","sequence":"additional","affiliation":[{"name":"Institute of Molecular Pathology, Vienna Biocenter, Vienna, Austria; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott W.","family":"Lowe","sequence":"additional","affiliation":[{"name":"Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricky W.","family":"Johnstone","sequence":"additional","affiliation":[{"name":"Cancer Therapeutics Program, Peter MacCallum Cancer Centre, East Melbourne, Australia;"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Smyth","sequence":"additional","affiliation":[{"name":"Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Australia;"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111809272428400_B1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1182\/blood-2010-06-288456","article-title":"A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors.","volume":"117","author":"Goldstein","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2019111809272428400_B2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1084\/jem.191.4.661","article-title":"Differential tumor surveillance by natural killer (NK) and NKT cells.","volume":"191","author":"Smyth","year":"2000","journal-title":"J Exp Med"},{"issue":"10","key":"2019111809272428400_B3","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.4049\/jimmunol.0903730","article-title":"Secretion of IFN-\u03b3 but not IL-17 by CD1d-restricted NKT cells enhances rejection of skin grafts expressing epithelial cell-derived antigen.","volume":"184","author":"Mattarollo","year":"2010","journal-title":"J Immunol"},{"issue":"12","key":"2019111809272428400_B4","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1084\/jem.20042280","article-title":"Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer.","volume":"201","author":"Smyth","year":"2005","journal-title":"J Exp Med"},{"issue":"9","key":"2019111809272428400_B5","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1084\/jem.20050953","article-title":"Differential antitumor immunity mediated by NKT cell subsets in vivo.","volume":"202","author":"Crowe","year":"2005","journal-title":"J Exp Med"},{"issue":"3","key":"2019111809272428400_B6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/ni.1841","article-title":"Raising the NKT cell family.","volume":"11","author":"Godfrey","year":"2010","journal-title":"Nat Immunol"},{"issue":"8","key":"2019111809272428400_B7","first-page":"3380","article-title":"Antitumor effect of alpha-galactosylceramide (KRN7000) on spontaneous hepatic metastases requires endogenous interleukin 12 in the liver.","volume":"6","author":"Fuji","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2019111809272428400_B8","first-page":"3702","article-title":"A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.","volume":"8","author":"Giaccone","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2019111809272428400_B9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3727\/096504001108747521","article-title":"Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with the melanoma B16 hepatic metastasis and immunohistological study of tumor infiltrating cells.","volume":"12","author":"Nakagawa","year":"2000","journal-title":"Oncol Res"},{"issue":"5","key":"2019111809272428400_B10","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.4049\/jimmunol.163.5.2387","article-title":"Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide.","volume":"163","author":"Toura","year":"1999","journal-title":"J Immunol"},{"issue":"6","key":"2019111809272428400_B11","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1002\/(SICI)1521-4141(199906)29:06<2014::AID-IMMU2014>3.0.CO;2-G","article-title":"Immunization with alpha-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis.","volume":"29","author":"Burdin","year":"1999","journal-title":"Eur J Immunol"},{"issue":"9","key":"2019111809272428400_B12","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1172\/JCI24762","article-title":"Glycolipid antigen induces long-term natural killer T cell anergy in mice.","volume":"115","author":"Parekh","year":"2005","journal-title":"J Clin Invest"},{"issue":"9","key":"2019111809272428400_B13","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1084\/jem.20042592","article-title":"Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients.","volume":"201","author":"Chang","year":"2005","journal-title":"J Exp Med"},{"issue":"9","key":"2019111809272428400_B14","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/ni827","article-title":"Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs.","volume":"3","author":"Fujii","year":"2002","journal-title":"Nat Immunol"},{"issue":"6","key":"2019111809272428400_B15","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1182\/blood-2006-12-061309","article-title":"An NKT-mediated autologous vaccine generates CD4 T cell-dependent potent anti-lymphoma immunity.","volume":"110","author":"Chung","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2019111809272428400_B16","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.4049\/jimmunol.178.5.2853","article-title":"Tumor cells loaded with \u03b1-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice.","volume":"178","author":"Shimizu","year":"2007","journal-title":"J Immunol"},{"issue":"11","key":"2019111809272428400_B17","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1084\/jem.20070458","article-title":"Cross-presentation of glycolipid from tumor cells loaded with \u03b1-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells.","volume":"204","author":"Shimizu","year":"2007","journal-title":"J Exp Med"},{"issue":"12","key":"2019111809272428400_B18","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1084\/jem.20021650","article-title":"A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma.","volume":"197","author":"Dhodapkar","year":"2003","journal-title":"J Exp Med"},{"issue":"4","key":"2019111809272428400_B19","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1046\/j.1365-2141.2003.04465.x","article-title":"Severe and selective deficiency of interferon-gamma-producing invariant natural killer T cells in patients with myelodysplastic syndromes.","volume":"122","author":"Fujii","year":"2003","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111809272428400_B20","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.1182\/blood-2007-05-092866","article-title":"Type I NKT cells protect (and Type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma.","volume":"111","author":"Renukaradhya","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2019111809272428400_B21","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ijc.11723","article-title":"CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates alpha-galactosylceramide presentation to natural killer T lymphocytes.","volume":"109","author":"Fais","year":"2004","journal-title":"Int J Cancer"},{"issue":"6","key":"2019111809272428400_B22","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/sj.leu.2402943","article-title":"Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells.","volume":"17","author":"Metelitsa","year":"2003","journal-title":"Leukemia"},{"issue":"4","key":"2019111809272428400_B23","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-2141.2010.08159.x","article-title":"Advances in the understanding of MYC-induced lymphomagenesis.","volume":"149","author":"Klapproth","year":"2010","journal-title":"Br J Haematol"},{"issue":"6046","key":"2019111809272428400_B24","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/318533a0","article-title":"The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice.","volume":"318","author":"Adams","year":"1985","journal-title":"Nature"},{"issue":"19","key":"2019111809272428400_B25","doi-asserted-by":"crossref","first-page":"8071","DOI":"10.1073\/pnas.0702294104","article-title":"Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B-cell lymphoma.","volume":"104","author":"Lindemann","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"2019111809272428400_B26","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1038\/sj.onc.1207674","article-title":"ETO interacting proteins.","volume":"23","author":"Hug","year":"2004","journal-title":"Oncogene"},{"issue":"1","key":"2019111809272428400_B27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nbt.1720","article-title":"Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi.","volume":"29","author":"Zuber","year":"2011","journal-title":"Nat Biotechnol"},{"issue":"4","key":"2019111809272428400_B28","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/intimm\/13.4.459","article-title":"NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma.","volume":"13","author":"Smyth","year":"2001","journal-title":"Int Immunol"},{"issue":"6","key":"2019111809272428400_B29","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1002\/eji.200939988","article-title":"IL-18, but not IL-15, contributes to the IL-12-dependent induction of NK-cell effector functions by Leishmania infantum in vivo.","volume":"40","author":"Haeberlein","year":"2010","journal-title":"Eur J Immunol"},{"issue":"11","key":"2019111809272428400_B30","doi-asserted-by":"crossref","first-page":"7002","DOI":"10.4049\/jimmunol.172.11.7002","article-title":"TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells.","volume":"172","author":"Papadakis","year":"2004","journal-title":"J Immunol"},{"issue":"10","key":"2019111809272428400_B31","doi-asserted-by":"crossref","first-page":"5894","DOI":"10.4049\/jimmunol.162.10.5894","article-title":"IL-18 and CD28 use distinct molecular mechanisms to enhance NK cell production of IL-12-induced IFN-gamma.","volume":"162","author":"Walker","year":"1999","journal-title":"J Immunol"},{"issue":"2","key":"2019111809272428400_B32","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1172\/JCI42314","article-title":"Mouse and human iNKT cell agonist beta-mannosylceramide reveals a distinct mechanism of tumor immunity.","volume":"121","author":"O'Konek","year":"2010","journal-title":"J Clin Invest"},{"issue":"11","key":"2019111809272428400_B33","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1084\/jem.20031192","article-title":"Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-galactosylceramide.","volume":"198","author":"Schmieg","year":"2003","journal-title":"J Exp Med"},{"issue":"6","key":"2019111809272428400_B34","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2174\/156652409788970706","article-title":"The contrasting roles of NKT cells in tumor immunity.","volume":"9","author":"Berzofsky","year":"2009","journal-title":"Curr Mol Med"},{"issue":"2","key":"2019111809272428400_B35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.clim.2010.10.005","article-title":"Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans.","volume":"140","author":"Metelitsa","year":"2011","journal-title":"Clin Immunol"},{"key":"2019111809272428400_B36","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0065-230X(08)00408-9","article-title":"The role of NKT cells in tumor immunity.","volume":"101","author":"Terabe","year":"2008","journal-title":"Adv Cancer Res"},{"issue":"2","key":"2019111809272428400_B37","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1084\/jem.20030324","article-title":"Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein.","volume":"198","author":"Fujii","year":"2003","journal-title":"J Exp Med"},{"issue":"10","key":"2019111809272428400_B38","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.4049\/jimmunol.171.10.5140","article-title":"NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.","volume":"171","author":"Hermans","year":"2003","journal-title":"J Immunol"},{"issue":"6","key":"2019111809272428400_B39","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ijc.20332","article-title":"Use of adenoviruses encoding CD40L or IL-2 against B-cell lymphoma.","volume":"111","author":"el Meziane","year":"2004","journal-title":"Int J Cancer"},{"issue":"2","key":"2019111809272428400_B40","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/bjc.1986.31","article-title":"Expression of MHC class II antigens in human B-cell leukaemia and non-Hodgkin's lymphoma.","volume":"53","author":"Guy","year":"1986","journal-title":"Br J Cancer"},{"issue":"8","key":"2019111809272428400_B41","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.4049\/jimmunol.1103582","article-title":"Role of gammadelta T cells in alpha-galactosylceramide-mediated immunity.","volume":"188","author":"Paget","year":"2012","journal-title":"J Immunol"},{"issue":"30","key":"2019111809272428400_B42","doi-asserted-by":"crossref","first-page":"11252","DOI":"10.1073\/pnas.0604812103","article-title":"Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice.","volume":"103","author":"Fujii","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2019111809272428400_B43","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2141.2007.06705.x","article-title":"Immunodeficiency and immunotherapy in multiple myeloma.","volume":"138","author":"Pratt","year":"2007","journal-title":"Br J Haematol"},{"issue":"13","key":"2019111809272428400_B44","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2019111809272428400_B45","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1073\/pnas.0711293105","article-title":"MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma.","volume":"105","author":"Jinushi","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2019111809272428400_B46","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1002\/ijc.22019","article-title":"Chemotherapy pretreatment sensitizes solid tumor-derived cell lines to Valpha24(+) NKT cell-mediated cytotoxicity.","volume":"119","author":"Mattarollo","year":"2006","journal-title":"Int J Cancer"},{"issue":"1","key":"2019111809272428400_B47","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0022-1759(00)00272-6","article-title":"Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15.","volume":"247","author":"van der Vliet","year":"2001","journal-title":"J Immunol Methods"},{"issue":"5","key":"2019111809272428400_B48","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1158\/1078-0432.CCR-04-1453","article-title":"A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer.","volume":"11","author":"Ishikawa","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2019111809272428400_B49","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood-2003-04-1155","article-title":"Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity.","volume":"103","author":"Nieda","year":"2004","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/15\/3019\/1358922\/zh804112003019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/15\/3019\/1358922\/zh804112003019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T13:30:53Z","timestamp":1687699853000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/15\/3019\/30623\/NKT-cell-adjuvantbased-tumor-vaccine-for-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,11]]},"references-count":49,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2012,10,11]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-04-426643","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,11]]}}}